13 Nov 2015 11:40
Ap27
Β
FORMΒ 38.5(b)
Β
IRISHΒ TAKEOVERΒ PANEL
Β
DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013
Β
DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY
Β
Β
1. KEYΒ INFORMATION
Β
Name of exempt principal trader | J.P. Morgan Securities LLC. |
Company dealt in | Pfizer Inc |
Class of relevant security to which the dealings being disclosed relate (Note 1) | Common Stock |
Date of dealing | 12 November 2015 |
Β
2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS
Β
(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)
Β
Class of relevant security: | Long | Short | ||||
Common Stock | Number | (%) | Number | (%) | ||
(1) Relevant securities | Β 5,061,776 0.08 | 2,679,291 0.04 | ||||
(2) Derivatives (other than options) | 1,309,645 0.02 | Β 2,498,367 0.04 | ||||
(3) Options and agreements to purchase/sell | Β 7,067,470 0.11 | Β 3,895,600 0.06 | ||||
Total | 13,438,891 0.21 | Β 9,073,258 0.14 Β | ||||
Β
Β
(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)
Β
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
Β
Ap28
Β
Β
3. DEALINGSΒ (NoteΒ 3)
Β
(a) PurchasesΒ andΒ sales
Β
Purchases/ sales Β | Number of relevant securities | Price per unit (USD) |
Purchases Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Sales | 15,800 2,400 13,400 2,896 3,900 100 5,042 72,142 7,900 17,505 113,073 2,900 200,370 3,013 4,300 1,750 849 18,400 1,986 300 864 3,500 43 200 Β 493,623 249 1,398 100 1 180 | 33.3600 33.3650 33.3700 33.3729 33.3750 33.3775 33.3788 33.3800 33.3809 33.3831 33.3844 33.3898 33.3900 33.3940 33.3950 33.3951 33.3952 33.4000 33.4015 33.4050 33.4100 33.4200 33.5700 33.5750 Β 33.3900 33.4905 33.5469 33.5500 33.5600 33.6028 |
Β
(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)
Β
Product name, e.g. CFD | Nature of transaction (Note 5) | Number of relevant securities (Note 6) | Price per unit (USD) (Note 4) |
Equity Swap Β Equity Link Note | Long Β Long Β Short | 180,184 Β 31,133 Β 31,133 31,133 | 33.7400 Β 32.1198 Β 32.1198 32.1198 Β |
Β
(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities
Β
Β
(i) Writing,Β selling,Β purchasingΒ orΒ varying
Β
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 4) |
Β
Β
(ii) Exercising
Β
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 4) |
Β
Β
(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)
Β
Nature of transaction (Note 7) | Details | Price per unit (if applicable) (Note 4) |
Β
Ap29
Β
4. OTHERΒ INFORMATION
Β
Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives
Β
FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ
underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ future
Β acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.
Β
Β
Β
Β
Β
Β
Β
Β
IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES
Β
Β
Date of disclosure | 13 November 2015 |
Contact name | Tung Le |
Telephone number | 020 7742 7272 |
Name of offeree/offeror with which connected | Allergan plc |
Nature of connection (Note 9) | Adviser to Allergan plc |
Β
Β
Β
SUPPLEMENTALΒ FORMΒ 38.5(b)
Β
Β
Β
Β
IRISHΒ TAKEOVERΒ PANEL
Β
DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013
Β
DETAILSΒ OFΒ OPENΒ POSITIONS
Β
(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 38.5(b))Β OPENΒ POSITIONSΒ (NoteΒ 1)
Β
Product name, e.g. call option | Written or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2)(USD) | Type, e.g. American, European etc. | Expiry date |
Call option | Purchased | 30,000 | 35.00 | American | 20/01/17 |
Call option | Purchased | 70,000 | 37.00 | American | 20/01/17 |
Call option | Purchased | 363,900 | 35.00 | American | 15/01/16 |
Call option | Purchased | 700 | 38.00 | American | 15/01/16 |
Call option | Purchased | 1,200,000 | 34.00 | American | 20/11/15 |
Call option | Purchased | 1,500,000 | 35.00 | American | 13/11/15 |
Call option | Written Β | 2,500 | 28.00 | American | 15/01/16 |
Call option | Written | 14,700 | 30.00 | American | 15/01/16 |
Call option | Written | 200 | 37.00 | American | 15/01/16 |
Call option | Written | 150,000 | 37.00 | American | 15/01/16 |
Call option | Written | 50,000 | 33.00 | American | 18/12/15 |
Call option | Written | 47,100 | 34.00 | American | 18/12/15 |
Call option | Written | 7,600 | 32.00 | American | 15/01/16 |
Call option | Purchased | 383,200 | 34.71 | European | 21/05/16 |
Call option | Purchased | 383,200 | 34.71 | European | 21/05/16 |
Call option | Purchased | 127,794 | 35.28 | European | 03/12/15 |
Call option | Purchased | 120,533 | 35.66 | European | 12/01/16 |
Call option | Purchased | 48,943 | 36.47 | European | 25/01/16 |
Call option | Purchased | 200,000 | 33.00 | European | 16/12/15 |
Call option | Written | 200,000 | 33.00 | European | 16/12/16 |
Call option | Written | 383,200 | 34.71 | European | 21/12/15 |
Put option | Written Β | 30,000 | 35.00 | American | 20/01/17 |
Put option | Written Β | 20,000 | 35.00 | American | 20/01/17 |
Put option | Written Β | 4,300 | 30.00 | American | 15/01/16 |
Put option | Written Β | 2,800 | 28.00 | American | 15/01/16 |
Put option | Written Β | 300 | 32.00 | American | 15/01/16 |
Put option | Written Β | 150,000 | 30.00 | American | 16/09/16 |
Put option | Written Β | 100,000 | 36.00 | American | 18/03/16 |
Put option | Written Β | 32,900 | 32.00 | American | 15/01/16 |
Put Option | Written | 1,500,000 | 35.00 | American | 17/06/16 |
Put option | Purchased | 9,200 | 33.00 | American | 19/02/16 |
Put option | Purchased | 19,100 | 31.00 | American | 19/02/16 |
Put option | Purchased | 5,300 | 23.00 | American | 15/01/16 |
Put option | Purchased | 100,000 | 30.00 | American | 15/01/16 |
Put option | Purchased | 5,600 | 25.00 | American | 15/01/16 |
Put option | Purchased | 250,000 | 28.00 | American | 15/01/16 |
Put option | Written | 200,000 | 33.00 | European | 16/12/16 |
Put Option | Purchased | 1,500,000 | 34.50 | American | 13/11/15 |
Put option | Purchased | 450,000 | 35.00 | American | 15/01/16 |
Callable Barrier Reverse Convertible Note | Purchased | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Purchased | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-callable Barrier Reverse Convertible Note | Purchased | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Purchased | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Purchased | 15,614+ | 29.12 | N/A | 12/09/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Leveraged Accumulator | Written | 15,614+ | 29.12 | N/A | 12/09/16 |
Leveraged Accumulator | Written | 9,000+ | 31.70 | N/A | 04/03/16 |
Auto-callable Optimization Securities | Written | 7,851 | 27.60 | N/A | 25/06/20 |
Equity Linked Note | Written | 6,740 | 29.67 | N/A | 03/02/16 |
Callable Barrier Reverse Convertible Note | Written | 183,430 | 32.71 | N/A | 21/03/17 |
Callable Barrier Reverse Convertible Note | Written | 30,572 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Written | 45,984 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Written | 30,408 | 34.53 | N/A | 05/04/16 |
Leveraged Accumulator | Written | 15,614+ | 29.12 | N/A | 12/09/16 |
Put Option | Purchased | 457,000 | 27.50 | N/A | 11/01/16 |
Callable Barrier Reverse Convertible | Purchased | 22,929 | 32.71 | N/A | 21/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 7,685 | 32.53 | N/A | 15/03/17 |
Auto-Callable Barrier Reverse Convertible Note | Purchased | 11,189 | 32.62 | N/A | 17/03/17 |
Barrier Reverse Convertible Note | Purchased | 178 | 2.44 | N/A | 05/04/16 |
Put Option | Written | 500,000 | 33.00 | American | 18/03/16 |
Put Option | Purchased | 1,000,000 | 33.50 | American | 20/11/15 |
+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price
Β
Notes
Β
1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionsΒ exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ any existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ mustΒ alsoΒ beΒ givenΒ onΒ this form.
Β
2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ mustΒ be stated.
Β
ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RulesΒ 8Β and
38.5Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.
Β
Β
Β
Follow the stocks